Swedish Patient Begins Producing Insulin Naturally After Groundbreaking Gene Therapy

For the first time, a man with type 1 diabetes in Sweden has regained the ability to naturally produce insulin—thanks to a pioneering gene-editing technique that could reshape treatment for the disease.

Type 1 diabetes occurs when the immune system destroys the pancreas’s insulin-producing cells. Until now, cell transplants required lifelong immunosuppressive medication to prevent rejection. But Swedish scientists have genetically modified donor pancreatic cells to avoid immune detection.

Using three precise gene edits, researchers removed the genes responsible for triggering immune responses and added protective proteins to shield the transplanted tissue. These edited cells were implanted into the patient’s forearm muscle and began producing insulin within four weeks.

Diabetes is a condition in which the body does not produce or properly use insulin, leading to elevated blood sugar levels.

Despite receiving only a small fraction of the required cell dose, the patient’s body continued producing insulin for at least 12 weeks—without any signs of immune rejection or the need for immune-suppressing drugs.

The biotech company behind the breakthrough, Sana Biotechnology, plans to launch clinical trials in 2026, offering new hope for millions living with type 1 diabetes.

Type 1 diabetes is an autoimmune condition marked by total insulin deficiency, unlike type 2, which involves reduced production and insulin resistance.